Physician profile
Edwin Yau
NPI 1316291925
$22,789.76
in general payments reported to CMS, 2019-2025
50 companies · $3,600 in 2025
The $3,600 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,095 · 2020: $205 · 2021: $2,836 · 2022: $7,214 · 2023: $3,874 · 2024: $3,966 · 2025: $3,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,420.68 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,233.91 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals Lp | $2,370.98 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $1,216.67 | 2021-2025 | |
| Abbvie INC. | $1,120.17 | 2021-2025 | Linzess, Viberzi, Ubrelvy |
| Glaxosmithkline, LLC. | $1,055.88 | 2021-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $820.55 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $765.65 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $521.00 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Regeneron Healthcare Solutions, INC. | $516.78 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $515.63 | 2023-2025 | Voquezna |
| Esperion Therapeutics, INC. | $509.30 | 2021-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $492.43 | 2022-2025 | |
| Ardelyx, INC. | $491.70 | 2023-2025 | Ibsrela |
| Sun Pharmaceutical Industries INC. | $486.08 | 2021-2025 | Cequa, Xelpros |
| Amarin Pharma, INC. | $480.46 | 2019-2022 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $438.17 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $434.95 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Ironwood Pharmaceuticals, INC | $344.15 | 2021-2025 | Linzess |
| Novo Nordisk INC | $291.01 | 2021-2025 | Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $283.70 | 2024-2025 | Symbravo, Auvelity |
| Lexicon Pharmaceuticals, INC. | $274.95 | 2023-2024 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $267.45 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Nestle Healthcare Nutrition INC. | $226.66 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $199.62 | 2021-2023 | Trintellix |
| Merz North America, INC. | $186.81 | 2022-2023 | Xeomin |
| Gilead Sciences, INC. | $184.93 | 2023-2025 | Vemlidy |
| Oyster Point Pharma, INC. | $176.18 | 2024-2025 | Tyrvaya |
| Vivus LLC | $169.40 | 2021-2025 | Pancreaze |
| Genzyme Corporation | $163.78 | 2023-2025 | |
| Radius Health, INC. | $154.63 | 2021-2025 | Tymlos |
| Madrigal Pharmaceuticals | $153.78 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $143.33 | 2019-2025 | |
| Corcept Therapeutics | $138.67 | 2023-2025 | Korlym |
| Astellas Pharma US INC | $130.73 | 2019 | |
| Abbott Laboratories | $109.83 | 2024-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Evoke Pharma, INC. | $104.54 | 2022 | |
| Aimmune Therapeutics, INC. | $103.40 | 2024-2025 | Zenpep |
| Scilex Pharmaceuticals INC. | $70.04 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $68.12 | 2021 | |
| Janssen Biotech, INC. | $57.30 | 2021-2024 | Tremfya |
| Dexcom, INC. | $51.27 | 2024-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $49.85 | 2023-2024 | Quviviq |
| Biohaven Pharmaceutical Holding Company Ltd. | $49.16 | 2022 | |
| Alk-Abello, INC | $44.33 | 2025 | Grastek, Odactra, Ragwitek |
| Hikma Pharmaceuticals USA | $23.70 | 2021 | |
| Eyevance Pharmaceuticals LLC | $23.70 | 2021 | |
| Argenx US, INC. | $21.80 | 2022 | |
| Exact Sciences Corporation | $21.01 | 2025 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $15.86 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.76 | 2023 | Ajovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Yau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.